Oklahoma HB2801 amends the vendor drug program to authorize the Oklahoma Health Care Authority to approve prior authorization for certain.
Oklahoma HB2801 amends the vendor drug program to authorize the Oklahoma Health Care Authority to approve prior authorization for certain antipsychotic drugs. The Authority is also directed to establish a prospective drug utilization review program for H2 Antagonists, ensuring compliance with FDA-approved product labeling. The bill specifies that certain drugs and medical uses are exempt from the program, including those used for weight gain, fertility, cosmetic purposes, and symptomatic relief of coughs and colds.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.